A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

Study acronym: MERCURY
StatusRecruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date: Sep 7, 2026 to Oct 13, 2026
    • Primary endpoints: details revised at 1 of 2 entries
    • Trial sites expanded: 12 → 20 locations
    • Eligibility criteria expanded, about 53 words
    • Secondary endpoints: details revised at 4 of 23 entries
  2. Trial sites expanded: 0 → 12 locationsv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2).
Trial Details
NCT Number NCT07598825
Lead Sponsor Amgen
Conditions
(from sponsor)		 Autoimmune Hepatitis, AIH
Related terms Hepatitis, Autoimmune
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov